Myovant Sciences Ltd. (MYOV)

NYSE: MYOV · IEX Real-Time Price · USD
13.50 -0.39 (-2.81%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap1.26B
Revenue (ttm)144.95M
Net Income (ttm)-238.46M
Shares Out93.31M
EPS (ttm)-2.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,081,445
Open13.75
Previous Close13.89
Day's Range13.18 - 14.00
52-Week Range13.14 - 27.43
Beta2.72
AnalystsBuy
Price Target28.00 (+107.4%)
Earnings DateJan 26, 2022

About MYOV

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility ...

IndustryBiotechnology
IPO DateOct 27, 2016
Employees407
Stock ExchangeNYSE
Ticker SymbolMYOV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for MYOV stock is "Buy." The 12-month stock price forecast is 28.00, which is an increase of 107.41% from the latest price.

Price Target
$28.00
(107.41% upside)
Analyst Consensus: Buy

News

Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, ...

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

1 week ago - GlobeNewsWire

Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

BASEL, Switzerland, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial results ...

1 week ago - GlobeNewsWire

Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Execut...

2 weeks ago - GlobeNewsWire

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Impr...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences, Inc. announced publication of patient-perception data for its FDA-approved OAB therapy, GEMTESA® (vibegron), compared to placebo.

1 month ago - Business Wire

Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of ...

LONDON and NEW YORK, Dec. 10, 2021 /PRNewswire/ -- Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and...

1 month ago - PRNewsWire

Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference

BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annua...

2 months ago - GlobeNewsWire

Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Resul...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Publication of Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

2 months ago - Business Wire

Nancy Valente, M.D. Joins Myovant Sciences' Board of Directors

BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the...

2 months ago - GlobeNewsWire

All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy

Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago - Zacks Investment Research

Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference

PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced ...

2 months ago - PRNewsWire

Why Did Myovant Sciences Shares Fall Despite Q2 Earnings Beat?

Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology. Pfizer declined ...

2 months ago - Benzinga

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 32.35% and 7.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates

BASEL, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the seco...

2 months ago - GlobeNewsWire

Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endome...

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its onc...

3 months ago - GlobeNewsWire

Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

3 months ago - Business Wire

Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26,...

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and con...

3 months ago - GlobeNewsWire

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissu...

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia

3 months ago - GlobeNewsWire

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactiv...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Presents Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Showing No Significant Effects on Blood Pressure or Heart Rate

4 months ago - Business Wire

Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

Other symbols:PFE
4 months ago - Zacks Investment Research

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Manag...

BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted fo...

4 months ago - GlobeNewsWire

Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for O...

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the Virtual 2021 Annual Meeting of the American Urological Association

4 months ago - Business Wire

Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Hea...

4 months ago - GlobeNewsWire

Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as ...

5 months ago - GlobeNewsWire

Here's Why Myovant Sciences Stock Is Falling Today

Second-quarter earnings results were a little bit disappointing.

5 months ago - The Motley Fool

Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research